Ratings Artelo Biosciences, Inc.

Equities

ARTL

US04301G5080

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.48 USD +0.68% Intraday chart for Artelo Biosciences, Inc. -1.33% +5.71%

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
+5.71% 4.69M - -
+2.73% 108B
B+
+9.59% 104B
B+
+6.58% 23.66B
B
-12.59% 22.1B
B+
-3.29% 19.71B
A-
-35.36% 18.2B
A-
-13.29% 16.19B
B
+4.68% 13.72B
C+
+34.25% 12.22B
C+
Investor Rating
-
Trading Rating
-
ESG Refinitiv
-

Financials

Sales growth
-
Earnings Growth
-
EBITDA / Sales
-
Profitability
-
Finances
-

Valuation

P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
-
4 months Revenue revision
-
7 days Revenue revision
-
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes